Qiagen stock is trading -25.66% below its average target price of $51.61 after dropping -1.8% during today's afternoon session. Analysts are giving the large-cap Biotechnology company an average rating of buy and target prices ranging from $42.5 to $64.0 per share.
Qiagen's short interest — meaning the percentage of the share float that is being shorted — is lower than average at 1.6%. The stock's short ratio is 2.62. Only 0.37% of the company's shares are owned by insiders, indicating that management does not have a deep alignment of interest with its shareholders.
Another number to watch is the company's rate of institutional share ownership, which now stands at 71.6%. In conclusion, we believe there is mixed market sentiment regarding Qiagen.
Institutions Invested in Qiagen
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2023-06-30 | Massachusetts Financial Services Co. | 9% | 21,184,160 | $812,730,333 |
| 2023-06-30 | Vanguard Group Inc | 4% | 8,592,033 | $329,633,360 |
| 2023-06-30 | Blackrock Inc. | 3% | 7,543,237 | $289,396,300 |
| 2023-06-30 | Amundi | 3% | 5,906,308 | $226,595,516 |
| 2022-12-31 | Norges Bank Investment Management | 3% | 5,741,604 | $220,276,647 |
| 2023-06-30 | Deutsche Bank Aktiengesellschaft | 2% | 4,729,615 | $181,451,687 |
| 2023-06-30 | FIL LTD | 2% | 4,496,775 | $172,518,780 |
| 2023-06-30 | Dz Bank Ag Deutsche Zentral Genossenschafts Bank, Frankfurt Am Main | 2% | 3,612,799 | $138,605,039 |
| 2023-06-30 | Wellington Management Group, LLP | 1% | 3,345,086 | $128,334,230 |
| 2023-06-30 | DekaBank Deutsche Girozentrale | 1% | 3,307,865 | $126,906,246 |
